» Articles » PMID: 12835670

Ovarian Cancer: Strategies for Overcoming Resistance to Chemotherapy

Overview
Journal Nat Rev Cancer
Specialty Oncology
Date 2003 Jul 2
PMID 12835670
Citations 520
Authors
Affiliations
Soon will be listed here.
Abstract

Ovarian cancer is responsible for 4% of deaths from cancer in women. Treatment comprises a combination of surgery and chemotherapy, but patients typically experience disease relapse within 2 years of the initial treatment. Further treatment can extend survival, although relapse eventually occurs again. A better understanding of the mechanisms that underlie this drug resistance should allow treatment to be optimized, so that substantial improvements in the outlook for women with this disease can be achieved.

Citing Articles

Transcriptome analysis of ovarian cancer uncovers association between tumor-related inflammation/immunity and patient outcome.

Wang J, Zhu W, Li X, Wu Y, Ma W, Wang Y Front Pharmacol. 2025; 16:1500251.

PMID: 39981173 PMC: 11839622. DOI: 10.3389/fphar.2025.1500251.


Nano-delivery of a novel inhibitor of ERCC1-XPF for targeted sensitization of colorectal cancer to platinum-based chemotherapeutics.

Mehinrad P, Abdelfattah A, Sadat S, Shafaati T, Elmenoufy A, Jay D Drug Deliv Transl Res. 2025; .

PMID: 39878858 DOI: 10.1007/s13346-024-01782-9.


Emerging roles of exosomes in diagnosis, prognosis, and therapeutic potential in ovarian cancer: a comprehensive review.

Tuscharoenporn T, Apaijai N, Charoenkwan K, Chattipakorn N, Chattipakorn S Cancer Gene Ther. 2025; 32(2):149-164.

PMID: 39843770 DOI: 10.1038/s41417-025-00871-2.


Combination of paclitaxel with rosiglitazone induces synergistic cytotoxic effects in ovarian cancer cells.

Patel B, Patel S, Modi F, Patel A, Gelat B, Tanavde V Sci Rep. 2024; 14(1):30672.

PMID: 39730440 PMC: 11680578. DOI: 10.1038/s41598-024-74277-9.


Prognostic and functional role of the nuclear export receptor 1 (XPO1) in gastrointestinal cancers: a potential novel target?.

Sokolova V, Gruber R, Pammer L, Kocher F, Klieser E, Amann A Mol Biol Rep. 2024; 52(1):87.

PMID: 39729162 PMC: 11680630. DOI: 10.1007/s11033-024-10169-5.